Articles Vol. 66 No. CĐ1-NCKH 24/01/2025

10. CLINICAL, LABORATORY CHARACTERISTICS OF WHITMORE CHILDREN PATIENTS TREATED AT THE NATIONAL CHILD’EN'S HOSPITAL

Le Thi Yen1,2, Nguyen Van Lam1,2, Tran Thanh Duong3,4, Hoang Thi Bich Ngoc1,2, Phan Thi Thu Chung1,2, Tran Minh Dien1,2
1 Vietnam National Children’s Hospital
2 Bệnh viện Nhi Trung ương
3 National Institute of Nutrition
4 Viện Dinh dưỡng Quốc gia
Corresponding author: Bslethiyen2111@gmail.com
DOI: 10.52163/yhc.v66iCD1.1972
89 Views
77 Downloads
Keywords
Whitmore disease B. pseudomallei children patient parotid abscess
Abstract

Whitmore is an infectious disease caused by the bacteria Burkholderia pseudomallei in humans and animals. It is not common in children but has diverse clinical features, difficult to diagnose, and a high mortality rate.

Objective: To describe the clinical and subclinical characteristics of Whitmore in patients treated at the National Children’s Hospital.

Research methods: Retrospective and prospective descriptive study on 45 children diagnosed with Whitmore and treated at the National Children’s Hospital from January 1, 2017 to December 31, 2023.

Results: Of the total 45 pediatric patients diagnosed with Whitmore. The number of patients ≤ 5 years old is 26 (57.8%), the male/female ratio is 2/1; 91.1% of patients have no underlying diseases. The most common clinical manifestation was angle-of-jaw abscess in 26/45 cases, accounting for 57.8%, and bacteremia in 12/45 cases, accounting for 26.7%. Septic shock accounted for 22.2% of children infected with Whitmore. The sensitivity rate of B. pseudomallei to Meropenem and Imipenem antibiotics was 100%. The resistance rate to Ceftazidime antibiotics was 2.5%; Amoxicillin/Clavulanic Acid was 5% and Trimethoprim/Sulfamethoxazole was 23.5%.

Conclusions: Whitmore is common disease in the age group ≤ 5, with the most common clinical presentation being parotid abscess accounting for 57.8%. The rate of bacteria sensitive to Carbapenem was 100% and the resistance rate to Ceftazidime was 2.4%.

References
[1]
Wiersinga W.J, Virk H.S, Torres A.G et al, Melioidosis, Nat Rev Dis Primers, 2018, 4 (1): 1-22. Google Scholar
[2]
Jarrett O, Seng S, Fitzgerald D.A, Paediatric melioidosis, Paediatr Respir Rev, Published online November, 24, 2023: S1526-0542(23)00079-9. Google Scholar
[3]
Meumann E.M, Limmathurotsakul D, Dunachie S.J, Wiersinga W.J, Currie B.J, Burkholderia pseudomallei and melioidosis, Nat Rev Microbiol, 2024, 22 (3): 155-169. Google Scholar
[4]
Bộ Y tế, Quyết định số 6101/QĐ-BYT ngày 30/12/2019 về việc ban hành Hướng dẫn chẩn đoán, điều trị bệnh Whitmore. Google Scholar
[5]
Arjun C, Moritz B, Thyl M, Keang S, Improving Treatment and Outcomes for Melioidosis in Children, Northern Cambodia, 2009-2018, Emerging infectious diseases, 2021, 27 (4). Google Scholar
[6]
Currie B.J, Ward L, Cheng A.C, The epidemiology and clinical spectrum of melioidosis: 540 cases from the 20 year Darwin prospective study, PLoS Negl Trop Dis, 2010, 4 (11): e900. Google Scholar
[7]
Easton A, Haque A, Chu K et al, A critical role for neutrophils in resistance to experimental infection with Burkholderia pseudomallei, J Infect Dis., 2007, 195 (1): 99-107. Google Scholar
[8]
Cheng A.C, Obrien M, Jacups S.P et al, C-reactive protein in the diagnosis of melioidosis, Am J Trop Med Hyg., 2004, 70 (5): 580-582. Google Scholar
[9]
Pham T.S, König E, Bui T.T et al, Newly detected paediatric melioidosis cases in a single referral children’s hospital in Ho Chi Minh city indicate the probable underrecognition of melioidosis in South Vietnam, Trans R Soc Trop Med Hyg., 2024, 118 (3): 190-198. Google Scholar
[10]
Vanaporn W, Premjit A, Natnaree S et al, Survey of antimicrobial resistance in clinical Burkholderia pseudomallei isolates over two decades in Northeast Thailand, Antimicrobial agents and chemotherapy, 2011, 55 (11). Google Scholar